BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 29
• 30

• Biotech Bay

  Exelixis, Inc. To Present At The Morgan Stanley Global Healthcare Conference On Tuesday, September 9

  September 9, 2014

   · 

  1 min read
• Business

  Acucela Inc. Appoints Biotechnology Industry Veteran And Former Pharmaceutical Executive, Brian O’Callaghan, As Its New President And Chief Operating Officer And Interim CFO; Ryo Kubota, MD, Phd, To Remain In His Role As Chairman And CEO

  September 9, 2014

   · 

  1 min read
• Biotech Bay

  BioTime CEO Dr. Michael D. West To Present At Rodman & Renshaw 16th Annual Healthcare Conference

  September 9, 2014

   · 

  1 min read
• Bio NC

  Massachusetts General Hospital Release: 2014 Chabner Colloquium Focuses On Collaboration In Cancer Trials

  September 9, 2014

   · 

  4 min read
• BioMidwest

  Clovis Oncology Announces Exercise In Full By Initial Purchasers Of Their Option To Purchase An Additional $37.5 Million Aggregate Principal Amount Of The Company’s 2.50% Convertible Senior Notes Due 2021

  September 9, 2014

   · 

  1 min read
• ProSensa Holding N.V. Announces 12 Presentations At The 19th International Congress Of The World Muscle Society In Berlin

  September 9, 2014

   · 

  6 min read
• Business

  Ligand Pharmaceuticals Inc. Licenses Captisol-Enabled™ Lamotrigine To CURx Pharmaceuticals

  September 9, 2014

   · 

  1 min read
• Deals

  Maker Of Robots For Parapalegics, ReWalk Readies For $50 Million IPO This Week

  September 9, 2014

   · 

  1 min read
• Pharm Country

  Elite Pharmaceuticals, Inc. Releases Positive Top Line Human Abuse Liability Data For ELI-200, An Opioid Abuse Deterrent Product

  September 9, 2014

   · 

  8 min read
• Drug Development

  Lipocine Inc. Announces First Patient Dosed In Phase 1 Study In Pregnant Women Of LPCN 1107, Potentially The First Oral Product For The Prevention Of Preterm Birth

  September 9, 2014

   · 

  3 min read